- £216.87bn
- £236.39bn
- $58.74bn
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)
Brief: Astrazeneca Says Baxfendy Recommended For Approval In The EU
Brief: Astrazeneca Says Imfinzi + EV Approved In US In Bladder Cancer
Brief: AstraZeneca Announces Klygefa Approved In The EU
Baxfendy recommended for approval in the EU
Imfinzi + EV approved in US in bladder cancer
Klygefa (gefurulimab) approved in the US
Klygefa (gefurulimab) approved in the EU
UK Stocks-Factors to watch on November 16
Brief: Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
Brief: FDA Approves Durvalumab With Enfortumab Vedotin-Ejfv For Muscle Invasive Bladder Cancer
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports (updated)
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
Brief: Astrazeneca Cuts 600 US Sales Staff As Savings Drive Kicks In- Bloomberg News
EU panel backs AstraZeneca hypertension drug baxdrostat
Brief: EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna